



ASX Announcement

For immediate release

14 August 2008

CSL COMPLETES INSTITUTIONAL EQUITY RAISING

CSL Limited (**CSL**) today announced the successful closure of the institutional component of the equity raising that forms part of the funding package for the proposed acquisition of Talecris Biotherapeutics Holdings Corp., as announced on 13 August 2008.

Following strong demand, the offer closed early and oversubscribed at a final price of A\$36.75 per share. A total of 47.5 million ordinary shares will be issued through this institutional placement, to raise approximately A\$1.75 billion. The new shares will represent approximately 8.6% of CSL's currently issued share capital, and are expected to be allotted and issued on 20 August 2008. The placement was arranged and underwritten by Merrill Lynch.

Dr Brian McNamee, Managing Director of CSL, said, "I am delighted by the response of the market to the announcement of the proposed acquisition of Talecris Biotherapeutics, as reflected by the level of interest in the institutional placement. CSL thanks its shareholders for their ongoing support, and looks forward to continuing to develop its global plasma therapeutics business which delivers benefits to patients and CSL's shareholders".

As previously announced, CSL will also offer eligible Australian and New Zealand registered shareholders the opportunity to subscribe for up to A\$5,000 worth of shares through a share purchase plan (**SPP**). The record date for the SPP will be 7.00 pm on 22 August 2008, and offers are expected to be sent to eligible shareholders in the last week of August.

For further information, please contact:

Investors	Media
Mark Dehring Director of Investor Relations Telephone: +61 3 9389 2818 Email: mark.dehring@csl.com.au	Rachel David Director of Public Affairs Telephone: +61 3 9389 1821 Mobile: +61 4 0177 5779 Email: Rachel.david@csl.com.au Tim Duncan Hinton & Associates Telephone: +61 3 9600 1979 Mobile: +61 4 0844 1122 Email: tduncan@hintons.com.au